Allopurinol

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Allopurinol

Examples of brand names: Zyloric [DE]

ATC code: M04AA01

Main use (for orientation): Hyperuricaemia/gout

Documented research summary

Allopurinol did not affect the investigated 7-OH-CBD metabolism in human liver S9/microsomes (2025). Limited negative in vitro finding, not clinical reassurance. The 2005 psoriasis article is a hypothesis review, not a combination study.

Uncertainties and limitations

Europe PMC full-text access failed; PMC web access required a browser check. Abstract assessed.

Missing data do not establish safety. Research is limited by the documented sources, search terms, languages and accessibility.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

7-OH-CBD (CBD metabolite) – laboratory and animal studies

Finding ID: B0426

Type of result: Negative experimental finding

Observation: Allopurinol did not change 7-OH-CBD metabolism in the investigated human liver S9/microsome model.

Mechanism: Examination of xanthine oxidoreductase involvement in further oxidation of 7-OH-CBD.

Study type: Original in vitro study

Context studied: Experimental metabolite model; endpoint 7-OH-CBD→7-formyl-/7-carboxy-CBD, not elimination of the parent CBD compound.

Clinical interpretation: Clinical significance unresolved

Limitations and uncertainties: Abstract reviewed; no quantitative clinical allopurinol–CBD study. A negative single endpoint does not establish general combination safety.

Original sources for this finding: NAD(P)+-dependent alcohol oxidoreductases oxidize 7-hydroxycannabidiol to a reactive formyl metabolite. [VD_MED_40736583]

References and access status

[VD_LABEL_D0174] ALLOPURINOL TABLET [UNICHEM PHARMACEUTICALS (USA), INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_40736583] NAD(P)+-dependent alcohol oxidoreductases oxidize 7-hydroxycannabidiol to a reactive formyl metabolite.

Original source / bibliographic reference

Authors: Wu Q, Fang JL, Nagumalli SK, Guo X, Beland FA.

Year: 2025

Source type: research-article; Journal Article

DOI: 10.1007/s00204-025-04140-x

PMID: 40736583

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility